Familial breast cancer BRCA trial

2 May 2006

A new international phase II clinical trial led by Breakthrough Breast Cancer and Cancer Research UK is to look at the effect of a novel form of drug treatment for metastatic hereditary breast cancer. More than three-quarters of all cases of familial breast cancer occur in individuals with mutations in the BRCA1 or BRCA2 genes, in whom the tumours are often more advanced than in other breast cancer patients, and around a quarter will have a recurrence of cancer following initial treatment.

More from us

Genomics and policy news